ClinicalTrials.Veeva

Menu
F

Fremantle Dermatology | Fremantle, Australia

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
Secukinumab
Metvix
Cemiplimab
PEP005
Risankizumab
Lebrikizumab
LY3041658
JNJ-64304500
CNTO 1959

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 41 total trials

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Active, not recruiting
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo
Drug: Eltrekibart
Locations recently updated

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.

Enrolling
Prurigo Nodularis
Drug: Placebo
Drug: Povorcitinib

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Active, not recruiting
Alopecia Areata
Drug: Upadacitinib
Drug: Placebo

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with at...

Enrolling
Atopic Hand and Foot Dermatitis
Drug: Lebrikizumab
Drug: Placebo

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Other: Placebo
Drug: PF-07275315

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

This study is researching an experimental drug called cemiplimab. The study is focused on Cutaneous Squamous Cell Carcinoma (CSCC) and Basal Cell Car...

Enrolling
Cutaneous Squamous Cell Carcinoma
Basal Cell Carcinoma
Drug: Cemiplimab

This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin...

Enrolling
Cutaneous Squamous Cell Carcinoma (CSCC)
Procedure: Standard of care
Drug: Cemiplimab

Trial sponsors

AbbVie logo
Lilly logo
Pfizer logo
Amgen logo
A
D
Galderma logo
Janssen (J&J Innovative Medicine) logo
P
Regeneron Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems